23 research outputs found
âNordslesvigeren er nr. 1â â regional identitet pĂ„ Ăstfronten 1914-1918
Historien om de nordslesvigske krigsdeltagere under 1. Verdenskrig er traditionelt blevet behandlet i et nationalt perspektiv. Her benĂŠvnes soldaterne oftest som âdanskeâ. Denne artikel undersĂžger, hvordan nordslesvigske soldater pĂ„ Ăstfronten selv udtrykte deres identitet i krigssituationen. Udgangspunktet er krigsdeltagernes beskrivelser af og syn pĂ„ dels de fĂŠllesskaber, de var en del af ved fronten, og dels de grupperinger, de ansĂ„ for deres modsĂŠtninger. Hovedpointen er, at det mest italesatte tilhĂžrsforhold blandt disse soldater var det regionale bĂ„nd til Nordslesvig
âVi ved bedst selv, hvad vi erâ: Kollektiv selvopfattelse blandt nordslesvigske krigsdeltagere, 1914-1918
FortĂŠllingen om det danske mindretal i Tyskland fra 1864-1920 kan efterlade det indtryk, at dansktalende nordslesvigere over en bred kam primĂŠrt fĂžlte sig som âdanskereâ. Dette gĂžr sig isĂŠr glĂŠdende i den mĂ„de mindretallets deltagelse, erfaringer og selvopfattelse under 1. Verdenskrig udlĂŠgges. I det beskedne omfang nordslesvigske soldaters selvopfattelse har vĂŠret under faghistorisk behandling, har spĂžrgsmĂ„let om netop nationalt sindelag ogsĂ„ ofte vĂŠret i centrum. I modsĂŠtning hertil er denne afhandling en mere Ă„ben undersĂžgelse af forskellige former for fĂŠllesskabsforstĂ„else i sammenhĂŠng med krigsdeltagelsen, og analysen tager udgangspunkt i en rĂŠkke udvalgte dansksindede nordslesvigske krigsdeltagere
Stroke genetics informs drug discovery and risk prediction across ancestries
Previous genome-wide association studies (GWASs) of stroke - the second leading cause of death worldwide - were conducted predominantly in populations of European ancestry(1,2). Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis(3), and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach(4), we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry(5). Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.</p
Stroke genetics informs drug discovery and risk prediction across ancestries
Previous genome-wide association studies (GWASs) of stroke â the second leading cause of death worldwide â were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (Pâ<â0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries